Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease

TESRA and ECLIPSE Investigators, Donavan T Cheng, Deog Kyeom Kim, Debra A Cockayne, Anton Belousov, Hans Bitter, Michael H Cho, Annelyse Duvoix, Lisa D Edwards, David A Lomas, Bruce E Miller, Niki Reynaert, Ruth Tal-Singer, Emiel F M Wouters, Alvar Agustí, Leonardo M Fabbri, Alex Rames, Sudha Visvanathan, Stephen I Rennard, Paul JonesHarsukh Parmar, William MacNee, Gerhard Wolff, Edwin K Silverman, Ruth J Mayer, Sreekumar G Pillai

Research output: Contribution to journalArticlepeer-review

Abstract

Emphysema in chronic obstructive pulmonary disease (COPD) can be characterized by high-resolution chest computed tomography (HRCT); however, the repeated use of HRCT is limited because of concerns regarding radiation exposure and cost.
Original languageEnglish
Pages (from-to)948-57
Number of pages10
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume188
Issue number8
DOIs
Publication statusPublished - 15 Oct 2013

Keywords

  • Aged
  • Biological Markers
  • Emphysema
  • Female
  • Humans
  • Lung
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Pulmonary Disease, Chronic Obstructive
  • Receptors, Immunologic
  • Severity of Illness Index
  • Tomography, Spiral Computed

Fingerprint

Dive into the research topics of 'Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this